Gb0139 galecto
WebJun 22, 2024 · Galecto has multiple clinical programs in fibrosis and cancer focused on galectin-3 and LOXL2, including an inhaled galectin-3 modulator (GB0139) currently in a …
Gb0139 galecto
Did you know?
WebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary ... WebDec 21, 2024 · Rationale High galectin-3 levels predict poor outcomes in patients with COVID-19. Galectin-3 activates monocytes and macrophages which are directly …
WebMay 22, 2024 · On May 6, Galecto announced that it had recruited more than 150 patients to date for its Phase IIb GALACTIC-1 study of GB0139 (formerly TD139) for idiopathic pulmonary fibrosis (IPF). GP0139 is an inhaled galectin-3 inhibitor. The company stated that its ability to recruit, especially in areas that have been most affected by Covid-19, namely ... WebJul 13, 2024 · Galecto anticipates that topline data from the GALACTIC-1 trial will be available by mid-2024. “We are pleased to continue our Phase 2b GALACTIC-1 trial of GB0139 in IPF patients. We believe the 3 mg dose of GB0139, as a single agent, has the potential to be an effective and potentially life-changing treatment.
WebAug 8, 2024 · Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute lung injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts in treatment is essential. GB0139 is a Gal-3 inhibitor currently under clinical investigation for the treatment of … WebApr 26, 2024 · The study is designed to investigate the safety and efficacy of Galecto’s most advanced compound, GB0139, in 141 patients with IPF. Patients in GALACTIC-1 …
WebAug 27, 2024 · GB0139 (formerly TD139) is an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs. The company is investigating GB0139 in its Phase 2b GALACTIC-1 clinical trial in IPF. ... Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and …
WebDec 21, 2024 · 10 mg GB0139 twice daily for 48 hours, then once daily for 14 days (n=20). Results: Patients aged 27–87 years were enrolled from July 2024; the final patient completed the 90-day follow-up in April 2024. GB0139+SOC was well tolerated with no treatment-related serious adverse events reported. Incidences of adverse events were shoes couplesWebMay 6, 2024 · GB0139 also induced profound biological changes in the cellular microenvironment of the lung that is believed to reduce fibrosis. About Galecto. Galecto … shoes courmayeurWebJan 1, 2024 · TD139 (GB0139) Galecto, Inc. (Copenhagen, Denmark) Dry powder inhaler QD • Phase Ia/Ib - safety, tolerability, PK and biomarkers in healthy volunteers and patients with IPF completed (NCT02257177). • Phase IIb - efficacy and safety study (GALACTIC-1, NCT03832946) in IPF patients. GB1211: Galecto, Inc. (Copenhagen, Denmark) Oral … shoes council bluffsWebApr 14, 2024 · On Wednesday, April 12th, Orbimed Advisors Llc sold 2,363 shares of Galecto stock. The stock was sold at an average price of $1.81, for a total transaction of … shoes cookeville tnWebNov 30, 2024 · Galecto is now investigating GB0139 (formerly TD139) in the Phase 2b/3 GALACTIC-1 clinical trial in IPF. The trial is a pivotal size, randomized, double-blind, … shoes coursesWebApr 13, 2024 · Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the … shoes cover machine dispenser manufacturerWebGalecto builds on more than 10 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. In addition to the lead product candidate, GB0139, the company’s ... shoes coventry